Kornimate/medical-research-clean huggingface dataset:
feasibility of pet-scan at day 1 of brachytherapy for patients with cervical cancer

Conditions: Cervical Cancer

Summary: interventional, exploratory, prospective and monocentric study which aim to study the feasibility of brachytherapy using a pet-scan

the study will proceed as follow: * initial check-up before the brachytherapy, including a clinical exam, collect of disease history and other informations that can be required for a good execution of the trial, and a usual patient care (chemotherapy with concomitant radiotherapy, biopsy, rmi, pet-scan and paraaortic lymphadenectomy). * additional pet-scan exam at day 1 of the brachytherapy (with collect of informations on toxicity, clinical morphology data and biomorphological data of rmi and pet-scan, and dosimetric study of the brachytherapy) * 4 months after the brachytherapy, additional pet-scan monitoring metabolic volumes and standardized metabolic fixation parameters

Eligibility criteria:
inclusion criteria: * patient suffering from a cervical cancer: * squamous-cell carcinoma or adenocarcinoma histologically proven * classified from figo 2009 ib2 to iva stage * age ≥ 18 years old * examination by pet-scan and pelvic rmi realized at diagnosis * examination by negative pet-scan remotely closed and at lymph node level * surgical lymphadenectomy negative at paraaortic level * treatment by external radiotherapy (doses between 45 gy and 50.4 gy in 1.8 gy/fractions) and concomitant chemotherapy (at least 4 cures per weeks using platinum salt) done * scheduled curative treatment by brachytherapy driven by rmi * affiliation to the national social security system * with informed and signed consent before any procedure specific to the study exclusion criteria: * performance status of who score \> 2 * other histology than squamous cell carcinoma or adenocarcinoma * metastatic patient or paraaortic node positive * adjuvant radiochemotherapy after the first surgery * dementia or psychiatric history * kidney failure * diabet * chronic inflammatory bowel disease * pelvic and/or vesicoureteral surgery history * pelvic irradiation history * other active neoplasia or \< 5 years old, except for basocellular carcinoma that can be locally treated * contraindication to one of the following procedure : rmi, pet-scan, general anesthesia * radiosensitive disease (fragile x syndrome, huntington's chorea, xeroderma pigmentosum, connective tissue disease) or signs of radiosensitivity. * treatment with palliative intent * pregnant or breastfeeding women * patient under guardianship or tutorship

Keywords: pet-scan brachytherapy cervical cancer
pilot clinical trial of the safety and efficacy of telmisartan for the mitigation of pulmonary and cardiac complications in covid-19 patients

Conditions: COVID-19

Summary: this study will enroll 40 symptomatic outpatients tested positive for coronavirus 2019 (covid-19). patients to be randomized 1:1 to telmisartan (40 mg) vs placebo to be administered orally once daily x 21 days. daily, the study patients will be asked to keep a record of the severity of their fever, dyspnea and fatigue and take their blood pressure (bp) and temperature. study visits to occur on day 1 (entry), day 4, day 10 and day 21. oro-pharyngeal swabs, and approximately 25 cc of blood will be collected at each study visit for safety labs and for the evaluation of the renin-angiotensin system (ras) system and for various blood biomarkers of inflammation, coagulation and fibrosis.


Eligibility criteria:
inclusion criteria: * able to provide written informed consent prior to initiation of any study procedures. * understands and agrees to comply with planned study procedures including self testing of blood pressure daily * male or non-pregnant female adult ≥18 years of age at time of enrolment. * has laboratory-confirmed severe acute respiratory syndrome corona virus 2 (sars-cov-2) infection as determined by fda-approved commercial or public health assay in any specimen collected ideally \< 72 hours prior to randomization. exceptions to the \<72 hr inclusion criteria may be made at the discretion of the investigator. * positive for covid-19 symptoms: fever defined as a temperature of \>100.4 on study screening or self-report of daily fever at home or shortness of breath of any degree or fatigue causing greater than minimal interference with usual social \& functional activities * women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study * able to easily swallow pills exclusion criteria: * immediate need for hospitalization on screening * systolic blood pressure less than 100 mmhg * self-reported presence of chronic kidney disease or requiring dialysis * self-reported history of liver failure or untreated hepatitis b or c * pregnancy or breast feeding * allergy to the study medication * current use of angiotensin receptor blocker (arb) or angiotensin converting enzyme (ace) inhibitor medications. other blood pressure medications will be permitted in the systolic bp is higher than 90 mmhg * prior reaction or intolerance to arb or ace inhibitor * use of aliskiren in patients with diabetes * current use of and on-going need for lithium, digoxin, potassium sparing diuretics such as spironolactone * current use of and need for potassium supplements * current or past participation in a research study within 12 weeks prior to the screening visit unless cleared by study team * inability to drive safely for study visits * subjects, who, in the opinion of the investigator, are unable to comply with the protocol evaluation, or for whom study participation may not be advisable
phase iii clinical trial of npb-01maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy.

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Summary: patients diagnosed with chronic inflammatory demyelinating polyneuropathy were confirmed based on the european federation of neurological societies/ peripheral. nerve society guideline. patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive npb-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. subsequently, patients receive npb-01 1g/kg every 3weeks and evaluate the inflammatory neuropathy cause and treatment（incat） score and incat sensory sumscore（iss） et al. as a safety endpoint, the safety of npb-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.


Eligibility criteria:
inclusion criteria: * 1. patients with progressive or relapsing motor and sensory dysfunction of more than one limb resulting from neuropathy within 2 months prior to the date informed consent is obtained. * 2. patients who incat score between 2-9. (if the incat score is 1 in upper limb, the incat score of 2 must be exclusively from leg disability to qualify.) * 3. patients who need high-dose intravenous immunoglobulin therapy. * 4. patients who continued treatment for cidp without addition or increase at 30 days before informed consent. * 5. patients with greater than or equal to twenty years old at informed consent. exclusion criteria: * 1. patients with evidence of myelopathy or demyelination of central nerve * 2. patients with evidence of stroke, central nerve system trauma, or persistent neurological deficits due to peripheral neuropathy from other causes（diabetic neuropathy, igm paraproteinaemia, uraemic neuropathy, toxic neuropathy, hereditary neuropathy） * 3. patients with evidence of neuropathy or alcoholic neuropathy or vitamin deficiency neuropathy due to myeloma, lymphoma, sarcoidosis, systemic lupus erythematosus, malignancy, vasculitis, crow-fukase syndrome, sjögren syndrome. * 4. patients with multifocal motor neuropathy. * 5. patients treated with plasmapheresis at 3 months before informed consent. * 6. patients treated with rituximab at 6 months before informed consent. * 7. patients treated with high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） at 8 weeks before informed consent. * 8. patients treated with intravenous immunoglobulin at 3 weeks before informed consent. * 9. patients with history of shock or hypersensitivity for npb-01. * 10. patients with iga deficiency. * 11. patients with malignancy at informed consent. * 12. patients with impaired liver function. * 13. patients with impaired renal function. * 14. patients with cerebro- or cardiovascular disorders. * 15. patients with high risk of thromboembolism. * 16. patients with hemolytic/hemorrhagic anemia. * 17. patients with decreased cardiac function. * 18. patients with decreased platelet.

Keywords: ivig in chronic inflammatory demyelinating polyneuropathy patients with chronic inflammatory demyelinating polyneuropathy
how future surgery will benefit from severe acute respiratory syndrome coronavirus 2 (sars-cov-2) related measures perspective from italian young surgeon society (spigc)

Conditions: COVID-19; Health Behavior

Summary: the coronavirus 2019 pandemic (covid-19) strongly affected clinical care worldwide. due to a shortage of hospitals and beds in intensive care units (icu), in italy during outbreaks, surgical resources were temporarily and partially shifted to covid-19 patients. in addition, the risk of cross-infection could have determined a shit in surgical perioperative care. to counterbalance these limitations, many centers routinely changed their clinical practice, which could be maintained by surgeons across italy. the aim of the present study is to evaluate how the covid-19 pandemic determined a change in daily clinical practice among all specialties.

the purpose of this investigation, organized by the italian young surgeon society (s.p.i.g.c.), is to establish the impact of the coronavirus 2019 pandemic (covid-19) on clinical care in italy. there will be collected from any italian surgeon (resident, fellow, doctor of philosophy (ph.d.) candidate, attending surgeon, professor) impressions by completing a survey on this topic. the analysis is divided into three study periods. for each question, participants must answer for each period. time frames were divided according to three distinct phases of the pandemic: pre-covid-19 period, covid-19 pandemic period, covid-19 endemic period. the pre-covid-19 period was defined between eighth march 2019 and seventh march 2020, whereas the covid-19 pandemic period was identified between the declaration of italian lockdown measures (eighth march 2020) until the release of this questionnaire (sixteenth march 2022) with the periodic pandemic outbreaks. finally, covid-19 endemic period was described as a future phase where lockdown measures and social distancing will be removed.

Eligibility criteria:
inclusion criteria: * resident, fellow, phd candidate, consultant or attending surgeon in italy in the following surgical specialties: cardiothoracic surgery, colon and rectal surgery, general surgery, gynecology and obstetrics, gynecologic oncology, neurological surgery, ophthalmic surgery, oral and maxillofacial surgery, orthopedic surgery, otorhinolaryngology, pediatric surgery, plastic and maxillofacial surgery, urology, and vascular surgery exclusion criteria: * undergraduate students * non-surgical consultant

Keywords: covid-19 survey enhanced recovery after surgery (eras) protocol perioperative management
prenatal pelvic floor prevention (3pn)

Conditions: Urinary Incontinence; Anal Incontinence; Genital Prolapse

Summary: objective: compare pelvic floor disorders (urinary incontinence, anal incontinence, genital prolapse, perineal pain, sexual troubles) 12 month after a first delivery between a group of women with prenatal pelvic floor exercises and a control group. hypothesis: prenatal pelvic floor exercises reduce postpartum urinary incontinence.

justification: pelvic floor disorders lead to handicap and medical care consumption. pregnancy and delivery are the main etiologies. pelvic floor exercises are proposed for prevention and may reduce immediate postpartum incontinence but we do not know if this preventive effect persists at 1 year. principal criteria: * urinary incontinence score at 12 months post-partum (iciq-sf) secondary criteria: * urinary incontinence prevalence at pregnancy end, 2 and 12 months post-partum * other pelvic floor disorders at pregnancy end, 2 and 12 months post-partum: symptoms questionnaires, qol questionnaire, pad-test, pop-q. * mode of delivery, length of active second phase, perineal tears, apgar score. * number of postpartum pelvic floor session, number of medical consultations, kegel exercises. progress: * inclusion between 20 and 28 weeks, initial assessment, randomization. * 8 sessions of pelvic floor exercises with a physiotherapist between 24 and 36 weeks versus written information only. * assessment at pregnancy end, 2 and 12 (+/-1) month post-partum study length: * for each women 18 months. * for each center 30 months. number of subjects: * to show a 1 point difference on iciq-sf score, we need 182 subjects (sd=2,4, a=0,05, β=0,20 bilateral test). * taking in account lost of follow-up (estimated 1/3) we are going to include 280 women.

Eligibility criteria:
inclusion criteria: * nulliparous * aged 18 years or more * pregnant between 20 and 28 weeks * french language reader exclusion criteria: * no medical insurance * multiple or pathologic pregnancy * previous pelvic floor exercises with a physiotherapist less than 6 months before pregnancy

Keywords: pelvic floor kegel exercises quality of life pelvic pain
n- homocysteinylated huntingtin in huntington's disease

Conditions: Huntington Disease

Summary: descriptive analysis of n- homocysteinylated huntingtin in 3 groups of human fibroblasts: 1. presymptomatic hd individuals with uhdrs motor ≤ 5 (mutated huntingtin), 2. symptomatic hd individuals with motor uhdrs \> 5 (mutated huntingtin) 3. human control cell lines, unmutated huntingtin

prospective inclusions of 32 subjects with 24 symptomatic hd patients and 8 presymptomatic hd patients.rationale: this is a pilot study in humans. over a period of 2 years, the potential recruitment should make it possible to include 32 patients this number will make it possible to calculate the overall variability of the dosage and to have statistics of position and dispersion in the 2 subgroups identified. controls: eight standardized cell lines from human fibroblasts

Eligibility criteria:
inclusion criteria: * patient with the symptomatic or presymptomatic huntington's disease gene (cag \>= 36) * molecularly confirmed huntington's disease * patient 18 years of age and older * person affiliated to or benefiting from a social security assurance exclusion criteria: * person deprived of liberty by a judicial or administrative decision, persons subject to psychiatric care pursuant to articles l. 3212-1 and l. 3213-1 * pregnant woman, parturient or nursing mother * women of childbearing potential who do not have effective contraception * intellectual deterioration preventing the understanding of research

Keywords: homocysteinemia
auscadasil: an australian cohort of cadasil

Conditions: Cadasil

Summary: the aim of this project is to establish an australian cohort of patients diagnosed with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil). this study will examine the clinical features and longitudinal course of cadasil. outcome measures include neuropsychological profile, neuroimaging, genetics, blood biomarkers, and retinal imaging.

using clinical examination, questionnaires, neuropsychological evaluation, brain mri, blood sample evaluation and retinal imaging, we aim to characterise the clinical profile and progression of cadasil in an australian cohort. this is multi-centre observational cohort study currently based at six sites (clinics, hospitals and universities) across three states in australia (new south wales, victoria and queensland). the multidisciplinary team aims to be the first to develop an australian cohort of cadasil which will contribute to global efforts and understanding of the disease.

Eligibility criteria:
inclusion criteria: 1. adults ≥18 years old 2. ability to provide written informed consent * a large-print version is available for individuals with visual impairment * an easy-to-read version is available for individuals with cognitive difficulties who may require extra support 3. ability to attend a testing site 4. ability to complete minimum dataset (medical examination and medical history questionnaire, blood test to determine genetic status and a short (20 minute) neuropsychology assessment). 5. cadasil participants according to one of the following categories: 1. confirmed diagnosis via genetic testing (notch3 pathogenic variant), or 2. suspected diagnosis based on medical history and brain mri, or 3. first degree relative of participant who is positive for notch3 pathogenic variant or 6. unrelated individual who is negative for the notch3 pathogenic variant, and has no cognitive complaints (i.e. control participant) exclusion criteria: 1. significant cognitive impairment leading to an inability to provide informed consent.

Keywords: cadasil clinical research genetics cognition neuroimaging blood markers retinal imaging
comparison of pain relief after arthroscopic knee surgery: adductor canal block and genicular nerve block

Conditions: Opioid Use; Pain Postoperative; Arthroscopic Knee Surgeries

Summary: this prospective randomized study aims to compare the analgesic efficacy of adductor canal block (acb) and genicular nerve block (gnb) groups to relieve postoperative pain in participants between ages of 18-72 undergoing arthroscopic knee surgery under spinal anesthesia. the main question it aims to answer is: to demonstrate whether adductor canal block or genicular nerve block is more effective in postoperative analgesia in patients undergoing arthroscopic knee surgery based on pain scores, opioid consumption and patient satisfaction. arthroscopic knee surgeries cause severe pain especially with movement in the post-operative period. after surgery, the movements of the participants are severely restricted because of pain, which increases the possibility of complications and postpones post-operative knee exercises. in this study, the participants' pain status, vas score, opioid consumption and patient satisfaction will be measured with a simple scoring system for 24 hours at predetermined time points and then compared. both types of blocks have pain-relieving effects. this study will only investigate which one is more effective in reducing pain, and there will be no deficiency in relieving the pain of the participants.


Eligibility criteria:
inclusion criteria: * voluntary willingness to participate in the study. * patients undergoing arthroscopic knee surgery (meniscus, acl, arthroscopic intervention etc). * asa i-ii-iii classification. * aged between 18-72 years. * no contraindications for regional anesthesia, and deemed suitable for regional anesthesia by the anesthesiologist. * undergoing surgery under spinal anesthesia. * fully oriented and able to cooperate. exclusion criteria: * undergoing surgery under general anesthesia. * chronic analgesic use. * presence of an active infection at the procedure site. * outside the appropriate age range. * inability to comply with postoperative pain/nrs follow-ups. * asa iv-v classification. * non-voluntary patients. * pregnancy.

Keywords: genicular nerve block arthroscopic knee surgery adductor canal block postoperative analgesia
formula diet treatment for nash patients.

Conditions: Steatohepatitis, Nonalcoholic

Summary: non-alcoholic steatohepatitis (nash) - also called fatty liver - is medically a serious problem because the liver tissue becomes fatty and stiff, and inflammatory reactions occur. this increases the risk of liver fibrosis (= scarring of the liver), liver cirrhosis (= shrunken liver), a liver tumor or death. so far there is no recognized treatment option for this disease. however, there is evidence that a lifestyle change based on a reduced carbohydrate diet, more exercise and a significant weight loss that can improve nash.

outpatients with nash will be included into this lifestyle intervention study. patients will get nutritional advices and a formula diet for 12 weeks. clinical visits will take place at baseline, after 4, 12 and after 52 weeks.

Eligibility criteria:
inclusion criteria: * bmi\>25 kg/qm exclusion criteria: * history of drug or alcohol abuse * acute or chronic diseases (except type 2 diabetes) * pregnancy or breast feeding

Keywords: overweight fatty liver
outcomes measures in intellectual disability

Conditions: Attention Deficit in Intellectual Disability

Summary: objective quantitative primary endpoints are lacking in clinical trials in intellectual disability. we propose to develop quantitative interactive attention evaluation criteria in patients with intellectual disability by using games on touchscreen and or eye tracking.

the aim of the study is to develop and validate quantitative interactive attention evaluation criteria by using games on touchscreen and or eye tracking in patients with intellectual disability. tests will have to be suitable whatever severity and etiology of intellectual disability. tests have to evaluate attention and concentration troubles in intellectual disability.once validated, tests could be used as outcome measures in clinical trials and as cognitive reeducation tools in intellectual disability.

Eligibility criteria:
inclusion criteria: 1. patients of both sex, with intellectual disability 2. minor patients 6 years old or more (age corresponding to the end of regression period observed in rett patients) or major protected patients 3. patients with more or less severe intellectual disability from various causes including fragile x syndrome, rett syndrome, angelman syndrome and other etiologies of intellectual disabilities and intellectual disabilities without identified etiology 4. affiliation to a social security system own or affiliated (excluding ame) 5. presence of parents or legal representative 6. informed consent signed by parents or legal representative exclusion criteria: 1. behavioral disorders not compatible with interactive tool (major agitation, straight and self aggressiveness) 2. uncontrolled seizure disorder despite treatment

Keywords: intellectual disability attention evaluation criteria games on touchscreen eye tracking